Vir Biotechnology, founded to harness immunology expertise, focuses on developing and commercializing therapeutics for viral and bacterial diseases. The company's core mission is to transform lives by powering the immune system through innovative treatments. Vir's product offerings include a robust pipeline of monoclonal antibodies (mAbs) optimized and engineered using artificial intelligence, targeting infectious and viral-associated diseases. Their market focus is primarily in California, addressing significant unmet medical needs.

Notable figures affiliated with Vir Biotechnology include leading scientists and industry experts who drive its research and development efforts. The company has attracted significant investment from prominent venture capital firms and strategic partners, bolstering its financial and operational capabilities. Key achievements include the development of several promising therapeutic candidates currently in clinical trials. Vir's impact is marked by its commitment to scientific innovation and potential to deliver groundbreaking treatments for infectious diseases.